Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

RESULTS FROM THE TWO PHASE 3 STUDIES SHOW THAT MOB-015 HAS UNIQUE ANTIFUNGAL EFFECT

textochbilcontainer

Moberg pharma intends to submit a registration application in Europe in 2021.

textochbilcontainer

We support Barncancerfonden

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.

Stockvalue

Subscribe

Get our latest press releases and reports

 

Latest report

2021-11-09 Interim report January - September 2021

Calendar/presentations

Next calendar event: 2021-12-09 Redeye Investor Forum